Pancreas-Targeted NIR Fluorophores for Dual-Channel Image-Guided Abdominal Surgery

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.7150/thno.10259</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890765">http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890765</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Pancreas-Targeted NIR Fluorophores for Dual-Channel Image-Guided Abdominal Surgery

Hideyuki Wada1,2, Hoon Hyun1, Christina Vargas1,3, Julien Gravier1,4, Gwang Li Park1, Sylvain Gioux1, John V. Frangioni1,5,6, Maged Henary1,7, and Hak Soo Choi1,8

1. Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215.
2. Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
3. Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA 02215.
4. INSERM, CRI, U823, Institut Albert Bonniot, 38042 Grenoble, France.
5. Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215.
7. Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303.
8. Department of Cogno-Mechatronics Engineering, Pusan National University, Busan 609-735, South Korea.

Abstract

Objective: Pancreas-related complications are some of the most serious ones in abdominal surgery. The goal of this study was to develop and validate novel near-infrared (NIR) fluorophores that would enable real-time pancreas imaging to avoid the intraoperative pancreatic injury.

Design: After initial screening of a large NIR fluorophore library, the performance of 3 selected pancreas-targeted 700 nm NIR fluorophores, T700-H, T700-F, and MB, were quantified in mice, rats, and pigs. Dose ranging using 25 and 100 nmol, and 2.5 µmol of T700-F, and its imaging kinetics over a 4 h period were tested in each species. Three different 800 nm NIR fluorophores were employed for dual-channel FLARE™ imaging in pigs: 2 µmol of ZW800-1 for vessels and kidney, 1 µmol of ZW800-3C for lymph nodes, and 2 µmol of ESNF31 for adrenal glands.

Results: T700-F demonstrated the highest signal to background ratio (SBR), with peak SBR at 4 h postinjection in mice. In pigs, T700-F produced an SBR ≥ 2 against muscle, spleen, and lymph nodes for up to 8 h after a single intravenous injection. The combination of T700-F with each 800 nm NIR fluorophore provided simultaneous dual-channel intraoperative imaging of pancreas with surrounding organs in real time.

Conclusion: Pancreas-targeted NIR fluorophores combined with the FLARE dual-channel imaging system enable the real-time intraoperative pancreas imaging which helps surgeons perform safer and more curative abdominal surgeries.

Key words: Pancreas-related complications, Postoperative pancreatic fistula, Intraoperative pancreatic injury, Image-guided surgery, Near-Infrared fluorescence.

Introduction

Pancreas-related complications in abdominal surgery are serious and sometimes fatal. Unrecognized intraoperative pancreatic injury results in many pancreas-related complications, such as postoperative pancreatic fistulae, peripancreatic abscesses, and pancreatitis [1,2]. These can progress to more serious complications such as intra-abdominal hemorrhage and septic shock, which result in longer hospital stays.
and higher medical costs [3]. The incidence of pancreas-related complications after gastrectomy with radical lymphadenectomy, which is the standard procedure in advanced gastric cancers, ranges from 5.8 to 49.7% [3-8]. Even performing laparoscopic gastrectomy, which offers a magnified view of the surgical field, reported complication rates range from 4.3 to 7.2% [1,2]. In addition to other gastrointestinal surgeries such as colectomy and splenectomy [9], urological surgeries including nephrectomy and adrenalectomy also have a high risk factor of pancreas-related complications [10].

Intraoperative pancreatic injuries are typically caused by the proximity of the pancreas to surrounding organs and the difficulty in distinguishing the edge of the pancreas from surrounding fat tissue, especially in obese patients. Real-time, high sensitivity identification of the pancreas intraoperatively could help avoid such injury. Previously we reported that near-infrared (NIR) fluorescent light could be used to identify both the pancreas and insulinoma by employing the clinically available NIR fluorophore methylene blue (MB) [11]. Although MB provided contrast between the pancreas and surrounding organs, it is not an ideal NIR contrast agent because of low signal intensity, nonspecific uptake, and short retention time in the pancreas.

Recently, we developed a library of NIR fluorophores targeted to various tissues and organs including thyroid and parathyroid [12], lymph nodes [13], nerves [14], adrenal glands [15], and bone [16] with high signal in the target and relatively low background after a single intravenous injection. Furthermore, screening the in vivo performance of our over 300 novel compounds, we found T700-F and T700-H could target the pancreas specifically. Combined with our FLARE intraoperative imaging system, which provides simultaneous dual-channel NIR fluorescence imaging along with color video, various surgeries can now be performed under real-time imaging along with color video, various guidance [17]. In this study, we hypothesized that the same approach could be used for pancreas imaging, and focused our experiments on novel agents that could outperform MB.

Materials and Methods

NIR Fluorescent Contrast Agents: Methylene blue (MB; USP 1%, 10 mg/mL) was purchased from Taylor Pharmaceuticals (Decatur, IL). T700-H and T700-F were synthesized as described in our previous reports [12,18-20], and served as pancreas targeting 700 nm emitting NIR fluorophores. Three different 800 nm NIR fluorophores including ZW800-1, ZW800-3C, and ESNF31, were also used for the dual channel imaging of surrounding tissue: ZW800-1 for NIR angiography and kidney imaging [21]; ZW800-3C for PLN imaging [13], and ESNF31 for adrenal glands [15]. MB was used as purchased without further treatment (31.3 mM), and all other NIR fluorophores were dissolved in dimethyl sulfoxide (DMSO) as a 10 mM stock solution.

Optical Property Measurements: Optical properties of NIR fluorescent contrast agents were measured in 100% fetal bovine serum (FBS) supplemented with 50 mM HEPES, pH 7.4. The quantum yield (QY) of 700 nm NIR fluorophores was measured using Oxazine 725 (Sigma-Aldrich) in ethylene glycol (QY = 19%) was used as a calibration standard under conditions of matched absorbance at 655 nm [22], while indocyanine green (ICG) in DMSO (QY = 13%) was used for the QY of 800 nm NIR fluorophores with a matched absorbance at 770 nm [23]. For in vitro optical property measurements, online fiberoptic HR2000 absorbance (200-1100 nm) and USB2000FL fluorescence (350-1000 nm) spectrometers (Ocean Optics, Dunedin, FL) were used. NIR excitation was provided by 5 mW of 655 nm red laser pointer (Opcom Inc., Xiamen, China) and 8 mW of 765 nm NIR laser diode light source (Electro Optical Components, Santa Rosa, CA) coupled through a 300 µm core diameter, NA 0.22 fiber (Fiberguide Industries, Stirling, NJ). In silico calculations of the distribution coefficient (logD at pH 7.4) and 3D minimized structures were calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, Hungary).

Animal Models: Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-certified facility and were studied under the supervision of Beth Israel Deaconess Medical Center’s Institutional Animal Care and Use Committee (IACUC) in accordance with approved institutional protocols #101-2011 for rodents and #034-2013 for pigs. Male CD-1 mice (n = 42) averaging 21 g and male Sprague-Dawley rats (n = 6) averaging 262 g (Charles River Laboratories, Wilmington, MA) were anaesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally (Webster Veterinary, Fort Devens, MA) and a midline laparotomy was performed to expose the viscera. Female Yorkshire pigs (n = 12) averaging 35.5 kg (E.M. Parsons and Sons, Hadley, MA) were induced with 4.4 mg/kg intramuscular Telazol (Fort Dodge Laboratories, Fort Dodge, IA) and intubated; anesthesia was maintained with 2% isoflurane (Baxter Healthcare, Deerfield, IL). Following anesthesia, a 14-G central venous catheter was inserted into the external jugular vein, and saline was administered as needed. A midline laparotomy and a left trans-rectus incision were performed for satisfactory intraoperative imaging. Electrocardiogram, heart rate, pulse
oximetry, and body temperature were monitored during the experiment.

**NIR Fluorescence Imaging System:** The dual-NIR channel FLARE imaging system has been described in detail previously [17,24]. In this study, 670 nm excitation and 760 nm excitation fluence rates used were 4.0 and 11.0 mW/cm², respectively, with white light (400 to 650 nm) at 40,000 lx. Color image and 2 independent channels (700 nm and 800 nm) of NIR fluorescence images were acquired simultaneously with custom software at rates up to 15 Hz over a 15-cm diameter field of view (FOV). In the color-NIR merged images, 700 nm NIR fluorescence and 800 nm fluorescence were pseudo-colored red and lime green, respectively. The imaging system was positioned at a distance of 18 inches from the surgical field. Camera exposure time and normalization were held constant for each experiment.

**Intraoperative Pancreas Imaging in Mice, Rats, and Pigs:** For initial in vivo screening, 25 nmol of T700-H and T700-F were injected intravenously into CD-1 mice 4 h prior to imaging (n = 3 per fluorophore). As a control, 120 nmol (1.5 mg/kg) of MB was injected 15 min prior to imaging (n = 3) [11]. In the dose optimization study, we injected 5 different doses of T700-F (0, 10, 25, 50, and 100 nmol) and images were taken at 4 h post-injection (n = 3 per each dose). For the kinetics study, we injected 25 nmol of T700-F intravenously and observed the fluorescent signal of pancreas at 6 different time points (0, 1, 2, 4, 8, and 24 h) (n = 3 per each time point). For rat studies, 1.2 µmol of MB (1.5 mg/kg) and 100 nmol of T700-F were injected intravenously 15 min and 4 h prior to imaging, respectively (n = 3 each NIR fluorophore). All NIR fluorophores except for MB were diluted into 5% dextrose in water (D5W) before injection, and 100 µL was injected into mice and 500 µL was injected into rats, respectively.

For large animal swine studies, 164 µmol (1.5 mg/kg) of MB and 2.5 µmol of T700-F were injected intravenously. We observed the fluorescent signals of viscera for 1 h post-injection, calculated a signal-to-background ratio (SBR) at 6 different time points (0, 3, 5, 15, 30, and 60 min), and compared the performance (n = 3 per each fluorophore). Next, we performed kinetics study using 2.5 µmol of T700F, and images were recorded at 11 different time points (0, 15, 30, 60, 90, 120, 180, 240, 300, 360, and 480) (n = 3). Finally, we tested dual-channel imaging of pancreas with surrounding vital tissues and organs including arteries, kidneys, pan lymph nodes (PLNs), and adrenal glands: 2 µmol of ZW800-1 for NIR arteriography and kidney imaging, 1 µmol of ZW800-3C for PLN imaging, and 2 µmol of ESNF31 for adrenal gland imaging (n = 1 for each study). The NIR angiography was recorded immediately after a single intravenous injection of ZW800-1 and kidneys were imaged 2 h post-injection. The PLN imaging was performed 4 h post-injection, while adrenal glands were imaged at 30 min post-injection. These imaging times were chosen based on prior optimization [13,15,25]. Each NIR agent was diluted into 10 mL of D5W prior to injection.

**NIR Fluorescence Microscopy:** For histological evaluations, pancreatic tissues were resected from rats after scheduled imaging using MB and T700-F, embedded in Tissue-Tek OCT compound (Fisher Scientific, Pittsburgh, PA), and flash frozen in liquid nitrogen. Tissue was cryosectioned at 10 µm intervals and observed using a NIR fluorescence microscope. Consecutive sections were stained with hematoxylin and eosin (H&E). NIR fluorescence microscopy was performed on a 4 filter-set Nikon Eclipse TE300 epifluorescence microscope to confirm the fluorescence of the pancreas as previously described [26,27]. The microscope was equipped with a 100 W mercury light source, NIR-compatible optics, and a NIR-compatible 4X, 10X, 20X, and 40X Plan Fluor objective lens (Nikon, Melville, NY). Custom filter sets (Chroma Technology Corporation, Brattleboro, VT) composed of a 650 ± 22 nm excitation filter and a 710 ± 25 nm emission filter were used to detect the pancreas fluorescence signal. Images were acquired on an Orca-AG (Hamamatsu, Bridgewater, NJ) and QImaging 12-bit camera for color imaging (Surrey, BC, Canada). Image acquisition and analysis was performed using iVision software (BioVision Technologies, Exton, PA).

**Quantitation and Statistical Analysis:** The fluorescent intensity (FI) of a region of interest (ROI) over the pancreas, rectus abdominis muscle, liver, spleen, duodenum, lymph nodes, and kidneys were quantified using custom FLARE software. The performance metric for this study was SBR. SBR = FI of ROI / background (BG) intensity. The rectus abdominis muscles, liver, spleen, duodenum, lymph nodes, and kidneys were used as BG compared to the signal in the pancreas to yield pancreas-to-muscle ratio (Pa/Mu), pancreas-to-liver ratio (Pa/Li), pancreas-to-spleen ratio (Pa/Sp), pancreas-to-duodenum ratio (Pa/Du), pancreas-to-lymph node ratio (Pa/LN), and pancreas-to-kidney ratio (Pa/Ki). At least 3 animals were analyzed for SBR at each time or dose point. Results were presented as mean ± standard deviation (SD). The statistical analysis was performed using the Unpaired T test between two groups and a one-way ANOVA followed by Tukey’s multiple comparisons test between multiple groups. A P value of less than 0.05 was considered significant: *P < 0.05, **P < 0.01, and ***P < 0.001.
Results

Optical properties of NIR fluorescent contrast agents. The chemical structure, absorbance, and fluorescence spectra for MB, T700-H, T700-F, ZW800-1, ZW800-3C, and ESNF31 are shown in Figure 1. Additionally, Table 1 details the optical properties of each NIR fluorophore in 100% serum. T700 fluorophores have 2-3 fold higher extinction coefficient and more than 3-fold higher QY compared to MB, which resulted in a total of 8-fold higher molecular brightness (Table 1). To summarize, MB, T700-H, and T700-F exhibited optical properties compatible with NIR fluorescence channel #1 (700 nm) of the FLARE imaging system, while ZW800-1, ZW800-3C, and ESNF31 were imaged using NIR fluorescence channel #2 (800 nm), which permits simultaneous, real-time, dual-channel intraoperative imaging.

A. 700 nm NIR Fluorophores

![Chemical Structure and Optical Properties of NIR Fluorophores](image)

B. 800 nm NIR Fluorophores

![Chemical Structure and Optical Properties of NIR Fluorophores](image)

Figure 1. Chemical Structure and Optical Properties of NIR Fluorophores. Chemical structure, molecular weight (MW), and logD at pH 7.4 were depicted using MarvinSketch (ChemAxon). Absorbance (Abs) and fluorescence (FL) emission spectra were measured in 100% fetal bovine serum at pH 7.4. a) 700 nm NIR Fluorophores. b) 800 nm NIR Fluorophores.
Initial in vivo screening in mice. Our NIR fluorophore library consists of over 300 novel compounds. Initial screening in mice revealed 2 pentamethine indocyanine fluorophores, T700-H and T700-F, with unusually high uptake in pancreas (Supplementary Material: Figure S1). T700-F showed a stronger pancreas signal and higher contrast to surrounding organs, such as duodenum, spleen, and liver. Both, however, also had strong kidney signal due to renal elimination. We then compared these two NIR fluorophores to clinically available MB in mice and re-measured SBR. As shown Figure 2A, T700-F showed the highest uptake in pancreas compared to others, and a significant improvement in SBR was found when compared with MB, which was injected at a 4-fold higher dose and exhibited a 10-fold shorter retention time [11]. Because T700-F demonstrated the highest SBR, we explored its dose optimization and kinetics, and expanded the study to 2 additional species, rats and pigs.

Kinetics and dose optimization of T700-F in mice. To optimize the best imaging time for pancreas (Pa), we injected 25 nmol of T700-F intravenously into CD-1 mice and measured the SBR of pancreas and surrounding tissues over the course of 24 h. As shown in Figure 2B, the highest SBR relative to liver (Li), spleen (Sp), and duodenum (Du), was achieved at 4 h post-injection although the background signal decreased continuously over time, the fluorescence signal of pancreas also diminished significantly after 4 h (Figure 2D). Therefore, dose optimization was performed at 4 h post-injection. Of note, no adverse reactions were encountered over the 24 h observation period.

For dose-optimization, we injected 5 different doses of T700-F (0, 10, 25, 50, and 100 nmol) into CD-1 mice, and images were acquired at 4 h post-injection. Signals in pancreas (Pa) increased proportionally to dose, but background signal in surrounding organs, including spleen (Sp) and duodenum (Du), rose significantly above the 25 nmol dose (Figure 2D). There was no significant difference in SBR of (Pa/Sp) and (Pa/Du) among 25 – 100 nmol groups (Figure 2C).

Intraoperative pancreas imaging and histology in rats. We compared T700-F with MB in SD rats by injecting 100 nmol of T700-F and 1.2 µmol (1.5 mg/kg) of MB, respectively (Figure 3A). Although MB highlighted the pancreas immediately after a single intravenous injection, the fluorescent signal in pancreas diminished rapidly after 15 min. Conversely, T700-F showed strong pancreas signal and low background uptake even at 4 h post-injection. After intraoperative imaging, we resected the pancreas and performed histological analysis (Figure 3B). NIR fluorescence microscopy confirmed 700 nm fluorescence signal in the resected pancreatic tissues. Both fluorophores accumulated in the intracellular space: T700-F stained the exocrine pancreas (acini; AC) cells and islets of Langerhans (IL), while MB exhibited proportionally higher islet uptake.

In vivo pancreas imaging in pigs. To confirm that small animal results were not species-dependent, we performed pancreas imaging in 35 kg Yorkshire pigs using 164 µmol (1.5 mg/kg) of MB and 2.5 µmol of T700-F. We administered more than a 65-fold higher dose of MB, however, pancreatic contrast diminished rapidly over time while T700-F showed an extremely strong pancreas signal (Figure 4A). Although the initial uptake of T700-F in spleen was higher than in the pancreas, the fluorescence signal in spleen decreased gradually and was negligible at 60 min post-injection. Adequate SBR (Pa/Mu) of MB was only seen for the initial 15 min and the SBR decayed by 60 min to almost the pre-injection level (Figure 4B). In contrast, T700-F maintained its SBR (Pa/Mu) of ≈ 5.0 for 60 min without detectable decrease and there was a significant difference in SBR (Pa/Mu) for 1 h between MB and T700-F. We further investigated the kinetics of T700-F for up to 8 h by comparing signals in the pancreas (Pa) with surrounding tissue and organs such as muscle (Mu), spleen (Sp), lymph nodes (Ln), and kidneys (Ki) (Figure 4C). Overall T700-F showed relatively high SBRs for up to 8 h without significant decrease in the pancreatic signal except for the SBR (Pa/Ki). Of note, no adverse reactions were encountered over the 8 h observation period.

Table 1. Optical properties of NIR fluorophores in 100% serum supplemented with 50 mM HEPES (pH 7.4).

<table>
<thead>
<tr>
<th>Optical Property</th>
<th>MB</th>
<th>T700-H</th>
<th>T700-F</th>
<th>ZW800-1</th>
<th>ZW800-3C</th>
<th>ESNF31</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLARE Imaging Channel</td>
<td>700 nm NIR (Channel #1)</td>
<td>123,000</td>
<td>249,000</td>
<td>309,000</td>
<td>135,000</td>
<td>14,580</td>
</tr>
<tr>
<td>Extinction Coefficient (M⁻¹cm⁻¹)</td>
<td>49,500</td>
<td>147,000</td>
<td>651</td>
<td>772</td>
<td>774</td>
<td>803</td>
</tr>
<tr>
<td>Absorbance Maximum (nm)</td>
<td>665</td>
<td>648</td>
<td>651</td>
<td>772</td>
<td>774</td>
<td>803</td>
</tr>
<tr>
<td>Emission Maximum (nm)</td>
<td>688</td>
<td>670</td>
<td>665</td>
<td>788</td>
<td>789</td>
<td>814</td>
</tr>
<tr>
<td>Quantum Yield (%)</td>
<td>9.6</td>
<td>30.4</td>
<td>29.9</td>
<td>15.1</td>
<td>16.1</td>
<td>10.8</td>
</tr>
<tr>
<td>Molecular Brightness (M⁻¹cm⁻²)</td>
<td>4,752</td>
<td>44,688</td>
<td>36,777</td>
<td>37,599</td>
<td>49,249</td>
<td>14,580</td>
</tr>
</tbody>
</table>

In silico calculations of logD at pH 7.4 and total polar surface area were calculated using Marvin and JChem calculator plugins (ChemiAxon, Budapest, Hungary).
Figure 2. Quantitative Evaluation of NIR Fluorophore Uptake in Mouse Pancreas: a) SBR (mean ± SD) of pancreas against liver, spleen, and duodenum was compared using various NIR fluorophores. b) Quantitative time-course assessment: 25 nmol of T700-F was injected intravenously into CD-1 mice, and SBR (Pa/Li), SBR (Pa/Sp) and SBR (Pa/Du) were measured at different time points (T = 0, 1, 2, 4, 8, and 24 h). c) Dose-response curve: 0, 10, 25, 50 and 100 nmol of T700-F were injected intravenously into CD-1 mice, and SBR (Pa/Li), SBR (Pa/Sp) and SBR (Pa/Du) were measured at 4 h post-injection. d) Real-time intraoperative imaging of pancreas in different time and doses. Controls were injected with DSW alone, and at least 3 animals were used for each data point. Scale bars = 0.5 cm. *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations used are: Du, duodenum; Li, liver; Pa, pancreas (arrow); Sp, spleen; St, stomach; Pa/Li, pancreas-to-liver ratio; Pa/Sp, pancreas-to-spleen ratio; Pa/Du, pancreas-to-duodenum ratio. All NIR fluorescence images have identical exposure times and normalizations.
Figure 3. Intraoperative Pancreas Imaging in SD Rats: a) 1.2 µmol of MB and 100 nmol of T700-F were injected intravenously 15 min and 4 h prior to imaging, respectively (n = 3). Abbreviations used are: Bl, bladder; Du, duodenum; In, intestine; Ki, kidney; Li, liver; Pa, pancreas; Sp, spleen. Arrows indicate pancreas and arrowheads indicate auto-fluorescence of food in lumen of intestine. Scale bars = 1 cm. All NIR fluorescence images have identical exposure times and normalizations. b) Histological analysis: Consecutive sections from rat pancreas stained with H&E or unstained were observed using an NIR fluorescence microscope. Abbreviations used are: Ac, acinus; IL, islets of Langerhans; PD, pancreatic duct. Scale bars = 300 µm. All NIR fluorescence images for each condition have identical exposure times and normalizations.
Figure 4. Intraoperative Pancreas Imaging in Pigs: a) 164 µmol of MB and 2.5 µmol of T700-F were injected intravenously into 35 kg Yorkshire pigs, and images were recorded over the course of 60 min (n = 3). Abbreviations used are: Du, duodenum; Ki, kidney; Li, liver; LN, lymph node; Pa, pancreas. All NIR fluorescence images have identical exposure times and normalizations. b) SBR (mean ± SD) comparison between MB and T700-F: SBR (Pa/Mu) was measured at different time points. ***P < 0.001. Statistical analysis between MB and T700-F was performed using unpaired t test. c) Quantitative time-course assessment of SBR (mean ± SD) for pancreas and surrounding organs/tissues were measured after 2.5 µmol of T700-F injection over the course of 8 h (n = 3). Abbreviations used are: Pa/Mu, pancreas-to-muscle ratio; Pa/Sp, pancreas-to-spleen ratio; Pa/LN, pancreas-to-lymph node ratio; Pa/Ki, pancreas-to-kidney ratio. Scale bars = 1 cm. All NIR fluorescence images have identical exposure times and normalizations.

Simultaneous dual-channel imaging of pancreas for image-guided abdominal surgery. Since the proximity of the pancreas to surrounding tissues and organs, such as arteries, lymph nodes, kidneys, and adrenal glands, is the main cause of intraoperative pancreatic injury, we explored simultaneous dual-channel imaging of pancreas. With the assistance of already developed 800 nm emitting NIR fluorophores [13,15,21], the FLARE imaging system enabled 700 nm and 800 nm NIR fluorescence imaging simultaneously in real time.

To identify blood vessels, ZW800-1 was injected intravenously into pig 4 h after injection of T700-F. As shown in Figure 5, we could visualize not only important arteries in gastrointestinal surgery such as the common hepatic artery, left gastric artery, and splenic artery, but also extremely small vessel branches from the common hepatic artery.

Because ZW800-1 is cleared from the body via renal excretion, we continuously imaged kidneys and found that kidney signal from ZW800-1 was highest at 2 h post-injection [21]. As shown in Figure 5, this permitted unambiguous identification of the boundary of pancreas from the kidney.

In subsequent experiments, we imaged peripancreatic lymph nodes by injecting ZW800-3C along with T700-F 4 h prior to imaging [13]. Lymph nodes were clearly visualized even when obscured by over-
lying pancreatic tissue, with the color merged image showing all desired surgical landmarks on one screen.

Finally, for dual-channel imaging of pancreas and adrenal glands, T700-F was injected 4 h prior to imaging, followed by injecting ESNF31 intravenously in the same pig 30 min prior to imaging [15]. Pancreas and adrenal glands were readily imaged using the 700 nm and 800 nm NIR channels, respectively. This dual-channel imaging permitted the pancreas to be distinguished from peripancreatic lymph nodes and the adrenal gland rather easily.

Discussion
Recent technical advances in abdominal surgery have made complex procedures safer and shorter. However, pancreas-related complications after gastrectomy with radical lymphadenectomy including peripancreatic lymph nodes resection, splenectomy, adrenalectomy, and nephrectomy remain unacceptably high [1,2,9,10]. Even with a magnified view provided by laparoscopy, it remains difficult to avoid pancreatic injury because of relatively poor contrast between pancreas and surrounding tissues and organs, and the inability of visible light to penetrate through blood and overlying tissue. NIR light has the potential to solve this problem because it can penetrate 5-8 mm into living tissue [28] and specific NIR contrast agents can be used to highlight specific anatomy. Importantly, NIR fluorescence imaging systems are now widely available for both open and minimally-invasive surgery.

Figure 5. Simultaneous Dual Channel Imaging of Pancreas and Surrounding Tissues and Organs: 2.5 µmol of T700-F was injected intravenously for pancreas imaging 4 h prior to:
1st row: NIR angiography with 2 µmol intravenous injection of ZW800-1 immediately prior to imaging. 2nd row: Kidney imaging with 2 µmol intravenous injection of ZW800-1 30 min prior to imaging. 3rd row: Pan lymph node imaging with 1 µmol intravenous injection of ZW800-3C 4 h prior to imaging. 4th row: Adrenal gland imaging with 2 µmol intravenous injection of ESNF31 30 min prior to imaging (n = 3 pigs). Shown are color image, 700 nm NIR fluorescence, 800 nm NIR fluorescence, and a merged image of the three. For the merged image, FLARE™ channel #1 (700 nm) is pseudo-colored in red and channel #2 (800 nm) in green. Abbreviations used are: AG, adrenal gland; CHA, common hepatic artery; Du, duodenum; In, intestine; Ki, kidney; Li, liver; LGA, left gastric artery; Pa, pancreas; Sp, spleen; St, stomach; SPA, splenic artery. Arrowheads indicate tiny branch from artery (1st row), kidney (2nd row), pan lymph nodes (3rd row), or adrenal gland (4th row). Scale bars = 1 cm. All NIR fluorescence images have identical exposure times and normalizations.
MB is a NIR fluorophore that we previously demonstrated can highlight the pancreas, and interestingly, insulinoma, however, it has relatively poor optical properties and short retention in the pancreas [11]. Out of over 300 candidates, T700-F showed significantly high uptake in pancreas and low background tissue uptake. Furthermore, its retention in pancreas was over 8 h, making this agent potentially useful in complex abdominal surgeries including laparoscopic operations (Figure 4C) [29]. Although the mechanism of specific pancreas uptake and retention of T700-F is currently unknown, it appears that the physicochemical properties of the substituted pentamethine play a key role for targeting. T700-F differs from T700-H by only 2 fluorine atoms, yet these atoms result in significantly improved pancreas selectivity.

There are some limitations, though, to the present study. First, our prototype pancreas-targeted compound T700-F emits at 700 nm where autofluorescence exists from fecal contents. A thorough bowel cleansing is therefore important. Development of an 800 nm version, which would solve this problem, is ongoing. Second, T700-F shows nonspecific uptake in kidneys, spleen, and lymph nodes and kidney, especially, has a higher signal than pancreas. However, as shown in Figure 5, this limitation is easily overcome by a low-dose injection of ZW800-1, which permits unambiguous separation of kidney from pancreas. Because first-in-human trials of ZW800-1 are imminent, it should be available for this application in the near future. Third, T700-F will require the same regulatory path as any drug prior to human use. Despite these limitations, this study lays the foundation for real-time intraoperative pancreas imaging during complex abdominal surgeries.

**Supplementary Material**

Fig.S1. http://www.thno.org/v05p0001s1.pdf

**Abbreviations**

NIR: near-infrared; MB: methylene blue; DMSO: dimethyl sulfoxide; FBS: fetal bovine serum; QY: quantum yield; ICG: indocyanine green; AAALAC: association for assessment and accreditation of laboratory animal care; IACUC: institutional animal care and use committee; FOV: field of view; D5W: 5% dextrose in water; SBR: signal-to-background ratio; PLN: pan lymph node; FL: fluorescent intensity; ROI: region of interest; BG: background; Pa/Mu: pancreas-to-muscle ratio; Pa/Li: pancreas-to-liver ratio; Pa/Sp: pancreas-to-spleen ratio; Pa/Du: pancreas-to-duodenum ratio; Pa/Ln: pancreas-to-lymph node ratio; Pa/Ki: pancreas-to-kidney ratio; SD: standard deviation; AC: acini; IL: islets of Langerhans; Pa: pancreas; Mu: muscle; Sp: spleen; Ln: lymph nodes; Ki: kidneys; MW: molecular weight; Abs: absorbance; FL: fluorescence; Du: duodenum; Li: liver; St: stomach; SD: Sprague-Dawley; Bl: bladder; In: intestine; PD: pancreatic duct; Pb: pancreas body; Ph: pancreas head; Pt: pancreas tail; AG: adrenal gland; CHA: common hepatic artery; LGA: left gastric artery; SPA: splenic artery.

**Acknowledgments**

We thank Rita G. Laurence for assistance with animal surgery, David Burrrington, Jr. for editing, and Eugenia Trabucchi for administrative assistance, and Frank Kettenring and Florin Neacsu for assistance with development and maintenance of the FLARE imaging system and software.

**Funding and all other required statements**

This study was supported by the following grants from the National Institutes of Health: NCI BRP grant #R01-CA-115296 (JVF), NIBIB grant #R01-EB-011523 (HSC), and a grant from the Dana Foundation (HSC). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Author’s Contributions**

HW, JVF, MH and HSC designed the study. HW, HH, CV, JG, GP and MH performed the experiments. HW, SG, JVF, MH and HSC reviewed, analyzed, and interpreted the data. HW, JVF, MH and HSC wrote and revised the paper. All authors discussed the results and commented on the manuscript. JVF, MH and HSC approved the submitted version.

**Competing Interests**

John V. Frangioni, M.D., Ph.D.: Dr. Frangioni is currently CEO of Curadel, LLC, which has licensed FLARE imaging systems and contrast agents from the Beth Israel Deaconess Medical Center.

**References**